Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLP-1002 for Osteoarthritis Pain
NCT05216341Phase 2Completed
- Sponsor
- OliPass Corporation
- Start
- Jan 2021
- Primary completion
- Sep 2023
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of OLP-1002 in osteoarthritis (OA), sponsored by OliPass Corporation. Started Jan 2021; status: completed.
02
Drugs
OLP-1002
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05216341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05216341.